WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004035036) A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/035036    International Application No.:    PCT/US2003/032554
Publication Date: 29.04.2004 International Filing Date: 15.10.2003
Chapter 2 Demand Filed:    13.05.2004    
IPC:
A61K 31/135 (2006.01), A61K 31/4164 (2006.01), A61K 31/55 (2006.01), A61K 45/06 (2006.01)
Applicants: WYETH [US/US]; Five Giralda Farms, Madison, NJ 07940 (US) (For All Designated States Except US).
DEECHER, Darlene, Coleman [US/US]; (US) (For US Only).
MERCHENTHALER, Istvan, Joseph [HU/US]; (US) (For US Only)
Inventors: DEECHER, Darlene, Coleman; (US).
MERCHENTHALER, Istvan, Joseph; (US)
Agent: LUCCI, Joseph; Woodcock Washburn LLP, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US)
Priority Data:
60/418,516 15.10.2002 US
10/685,974 14.10.2003 US
Title (EN) A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY
(FR) METHODE DE TRAITEMENT DES SYMPTOMES VASOMOTEURS COMPRENANT UN COMPOSE PRESENTANT UNE ACTIVITE INHIBITRICE DU RECAPTAGE DE LA NORADRENALINE ET UNE ACTIVITE ANTAGONISTE DU RECEPTEUR 5-HT2A
Abstract: front page image
(EN)The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the treatment of vasomotor symptoms such as thermoregulatory disorders. Furthermore, the present invention relates to the use of compounds and compositions of compounds having norepinephrine reuptake inhibitor (NRI) activity alone or norepinephrine reuptake inhibitor and serotonin reuptake inhibitor (NRI/SRI) dual activity in combination with 5-HT2a receptor antagonist activity.
(FR)L'invention concerne l'utilisation de composés et d'une composition de composés qui modulent les taux de noradrénaline pour le traitement des symptômes vasomoteurs tels que les troubles de la thermorégulation. L'invention concerne également l'utilisation de composés et de compositions de composés présentant une activité unique d'inhibition du recaptage de la noradrénaline (NRI) ou une activité double de d'inhibition du recaptage de la noradrénaline et d'inhibition du recaptage de la sérotonine (NRI/SRI) conjointement avec une activité antagoniste du récepteur 5-HT2a.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)